Literature DB >> 11435788

Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression.

S J Read1, A A Parsons, D C Harrison, K Philpott, K Kabnick, S O' Brien, S Clark, M Brawner, S Bates, I Gloger, J J Legos, F C Barone.   

Abstract

Sequencing of the human genome is nearing completion and biologists, molecular biologists, and bioinformatics specialists have teamed up to develop global genomic technologies to help decipher the complex nature of pathophysiologic gene function. This review will focus on differential gene expression in ischemic stroke. It will discuss inheritance in the broader stroke population, how experimental models of spontaneous stroke might be applied to humans to identify chromosomal loci of increased risk and ischemic sensitivity, and also how the gene expression induced by stroke is related to the poststroke processes of brain injury, repair, and recovery. In addition, we discuss and summarise the literature of experimental stroke genomics and compare several approaches of differential gene expression analyzes. These include a comparison of representational difference analysis we have provided using an experimental stroke model that is representative of stroke evolution observed most often in man, and a summary of available data on stroke differential gene expression. Issues regarding validation of potential genes as stroke targets, the verification of message translation to protein products, the relevance of the expression of neuroprotective and neurodestructive genes and their specific timings, and the emerging problems of handling novel genes that may be discovered during differential gene expression analyses will also be addressed.

Entities:  

Mesh:

Year:  2001        PMID: 11435788     DOI: 10.1097/00004647-200107000-00001

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  16 in total

1.  Assessment of protein expression levels after transient global cerebral ischemia using an antibody microarray analysis.

Authors:  Maria Irene Ayuso; Lidia García-Bonilla; Maria Elena Martín; Matilde Salinas
Journal:  Neurochem Res       Date:  2010-05-11       Impact factor: 3.996

2.  Impact of genetic testing on complex diseases.

Authors:  M J E van Rijn; C M van Duijn; A J C Slooter
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform.

Authors:  James K T Wang; Stuart Portbury; Mary Beth Thomas; Shawn Barney; Daniel J Ricca; Dexter L Morris; David S Warner; Donald C Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-22       Impact factor: 11.205

Review 4.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 5.  All's well that transcribes well: non-coding RNAs and post-stroke brain damage.

Authors:  Raghu Vemuganti
Journal:  Neurochem Int       Date:  2013-08-15       Impact factor: 3.921

Review 6.  Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.

Authors:  Andrea Lippoldt; Andreas Reichel; Ursula Moenning
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Neuroprotection by endogenous and exogenous PACAP following stroke.

Authors:  Yun Chen; Babru Samal; Carol R Hamelink; Charlie C Xiang; Yong Chen; Mei Chen; David Vaudry; Michael J Brownstein; John M Hallenbeck; Lee E Eiden
Journal:  Regul Pept       Date:  2006-10-04

Review 8.  Neurobiology of rehabilitation.

Authors:  Bruce H Dobkin
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

9.  Molecular mechanisms underlying hypothermia-induced neuroprotection.

Authors:  Yasushi Shintani; Yasuko Terao; Hiroyuki Ohta
Journal:  Stroke Res Treat       Date:  2010-12-01

Review 10.  Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2009-04-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.